Drugs / Bovine Intestinal Alkaline Phosphatase
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01416493 | May 2011 → Apr 2013 | rheumatoid arthritis | Alloksys Life Sciences B.V. | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT00511186 | May 2008 → Dec 2009 | infectious disease with sepsis | AM-Pharma | Terminated | Met primary |
| Phase 2 | NCT00727324 | May → Nov 2006 | ulcerative colitis | AM-Pharma | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01010724 | — | coronary artery disorder | Catharina Ziekenhuis Eindhoven | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01144611 Comparator | Apr 2010 → Dec 2013 | — | Alloksys Life Sciences B.V. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-08-02 | Alloksys Life Sciences B.V. | Results Alloksys reports interim results of its clinical phase IIb trial with Alkaline Phosphatase therapy RESCAP® in critical care patients alloksys.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-08-02 | Alloksys Life Sciences B.V. | Alloksys reports interim results of its clinical phase IIb trial with Alkaline Phosphatase therapy RESCAP® in critical care patients alloksys.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bovine intestinal alkaline phosphatase | “Bovine Intestinal Alkaline Phosphatase (BIAP) Intravenous administration of 10" bolus (67,5U/kg) and 48h continuous infusion (132,5U/kg)” NCT00511186 ↗ |
| Known as | BIAP | “Bovine Intestinal Alkaline Phosphatase (BIAP) Intravenous administration of 10" bolus (67,5U/kg) and 48h continuous infusion (132,5U/kg)” NCT00511186 ↗ |
| Modality | Protein / enzyme biologic | “Oral AP enzyme” PMID 19885903 ↗ Jul 2010 |
| Route | Intravenous | “AP is administered intravenously over 48 hours.” NCT00511186 ↗ |